In a report released on September 19, Thomas Smith from SVB Securities reiterated a Buy rating on Dice Therapeutics (DICE – Research Report), with a price target of $46.00. The company’s shares closed yesterday at $19.09.
Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, 89bio, and Prometheus Biosciences. According to TipRanks, Smith has an average return of -11.2% and a 33.04% success rate on recommended stocks.
Dice Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $39.75, implying a 108.22% upside from current levels. In a report released on September 14, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $36.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $38.18 and a one-year low of $12.64. Currently, Dice Therapeutics has an average volume of 417K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DICE Therapeutics Inc is a biopharmaceutical company leveraging proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas.
Read More on DICE:
